Device/Diagnostics Quarterly Deal Statistics, Q2 2016

A look at financing, M&A and alliance activity April–June 2016

 
• By Amanda Micklus and Maureen Riordan

Medtech companies brought in $1.5 billion in Q2 2016, 15% less than Q1, with debt offerings accounting for more than half the total; acquisitions more than doubled due to Abbott's $25 billion takeover of St. Jude Medical. Diagnostics financings were down 34% from Q1 and acquisition volume, also lower, was mainly Thermo Fisher Scientific's $4.2 billion buy of FEI.

IV1608_Calendar-apri-june

The device industry pulled in $1.5 billion in financing during the second quarter of 2016, a 15% drop from Q1's $1.8 billion. Once again, debt offerings played a big role, representing more than half of the aggregate. Similarly, there was also another strong showing from late-stage venture rounds. (See Exhibit 1.)

Open

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deal-Making

More from In Vivo